Infectious Agents Causing Abortion Among Pregnant Women : An Article Review
DOI:
https://doi.org/10.55544/sjmars.4.6.3Keywords:
TORCH infections, Listeria monocytogenes, zoonotic pathogens, vertical transmission, maternal–fetal infectionAbstract
Background: Abortion is a spontaneous loss of pregnancy before 20 weeks. Approximately 42 million pregnancies end in abortion. The maternal infections that are transmissible from mother to fetus are caused by many pathogens, of which the TORCH complex contributes majorly to neonatal and infant deaths globally.
The aim of this study is to identify the prevalence and types of infectious causes of abortion, modes of transmission, and methods of prevention and treatment.
Conclusions: abortion occurs during the first three months of pregnancy and is due to several reasons, including infection during pregnancy. This infection affects the pregnancy and causes many health problems for the mother and fetus that lead to abortion.
References
[1] AlEidan, I. M., Alghaneem, S. G., AlMosfer, W. A., & AlZahrani, A. A. (2017). Prevalence and risk factors of abortion in Almajmaah City, Kingdom of Saudi Arabia. International Journal of Scientific & Engineering Research, 8, 518–521.
[2] Giakoumelou, S., Wheelhouse, N., Cuschieri, K., Entrican, G., Howie, S. E. M., & Horne, A. W. (2016). The role of infection in miscarriage. Human Reproduction Update, 22, 116–133.
[3] Ford, H. B., & Schust, D. J. (2009). Recurrent pregnancy loss: Etiology, diagnosis, and therapy. Reviews in Obstetrics & Gynecology, 2, 76–83.
[4] Dimitriadis, E., Menkhorst, E., Saito, S., Kutteh, W. H., & Brosens, J. J. (2020). Recurrent pregnancy loss. Nature Reviews Disease Primers, 6, 98.
[5] Wang, Y., Li, S., Ma, N., Zhang, Q., Wang, H., Cui, J., et al. (2019). The association of TORCH infection and congenital malformations: A prospective study in China. European Journal of Obstetrics & Gynecology and Reproductive Biology, 240, 336–340.
[6] Sirin, M. C., Agus, N., Yilmaz, N., Bayram, A., Derici, Y. K., Samlioglu, P., et al. (2017). Seroprevalence of Toxoplasma gondii, rubella virus and cytomegalovirus among pregnant women and the importance of avidity assays. Saudi Medical Journal, 38, 727–732.
[7] Mocanu, A. G., Stoian, D. L., Craciunescu, E. L., Ciohat, I. M., Motofelea, A. C., Navolan, D. B., et al. (2022). The impact of latent Toxoplasma gondii infection on spontaneous abortion history and pregnancy outcomes: A large-scale study. Microorganisms, 10, 1944.
[8] Baghel, S., & Inamdar, S. A. (2020). TORCH infection and its influence on high-risk pregnancy. Journal of South Asian Federation of Obstetrics and Gynaecology, 12, 377–382.
[9] Lamichhane, S., Subedi, S., Pokharel Ghimire, S., Chetri, M., & Banerjee, B. (2016). Relationship of TORCH profile in first trimester spontaneous miscarriage. Journal of Nobel Medical College, 5, 17–21.
[10] Megli, C. J., & Coyne, C. B. (2022). Infections at the maternal–fetal interface: An overview of pathogenesis and defence. Nature Reviews Microbiology, 20, 67–82.
[11] Moseson, H., Jayaweera, R., Egwuatu, I., Grosso, B., Kristianingrum, I. A., Nmezi, S., et al. (2022). Effectiveness of self-managed medication abortion with accompaniment support in Argentina and Nigeria (SAFE). The Lancet Global Health, 10(1), e105–e113.
[12] Latt, S. M., Milner, A., & Kavanagh, A. (2019). Abortion laws. The Lancet, 393, xx–xx.
[13] Poudyal, A., Poudyal, N., & Khanal, B. (2018). Seroprevalence of TORCH infection—A laboratory profile. International Journal of Biomedical Research, 9, 154–157.
[14] Campero, L. M., Schott, F., Gottstein, B., Deplazes, P., Sidler, X., & Basso, W. (2020). Detection of antibodies to Toxoplasma gondii in oral fluid from pigs. International Journal for Parasitology, xx–xx.
[15] Nigro, G., Mazzocco, M., Mattia, E., Di Renzo, G. C., Carta, G., & Anceschi, M. M. (2011). Role of infections in recurrent spontaneous abortion. Journal of Maternal-Fetal & Neonatal Medicine, 24, 983–989.
[16] Laboudi, M., Taghy, Z., Duieb, O., et al. (2021). Toxoplasma gondii seroprevalence among pregnant women in Rabat, Morocco. Tropical Medicine and Health, 49, xx–xx.
[17] Alghamdi, A. J., Alabbas, A., Tadla, M., Agyemfra-Kumi, C., & Furmaga-Jablońska, W. (2017). Is congenital toxoplasmosis still an important clinical problem? Journal of Pre-Clinical and Clinical Research, 11(2), 167–170.
[18] Fisch, D., Clough, B., & Frickel, E. M. (2019). Human immunity to Toxoplasma gondii. PLoS Pathogens, 15, e1007927.
[19] Chaechi Nosrati, M. R., Shemshadi, B., Shayan, P., Ranjbar Bahadory, S., & Eslami, A. (2020). Serological determination of Toxoplasma gondii among sheep in Guilan Province, Iran. Archives of Razi Institute, xx–xx.
[20] Dubey, J. P. (2010). Toxoplasmosis of animals and humans (2nd ed.). CRC Press.
[21] Boyer, K., Hill, D., Mui, E., Wroblewski, K., Karrison, T., Dubey, J. P., et al. (2011). Unrecognized ingestion of Toxoplasma gondii oocysts leads to congenital toxoplasmosis. Clinical Infectious Diseases, 53, 1081–1089.
[22] Demar, M., Hommel, D., Djossou, F., et al. (2012). Acute toxoplasmosis in immunocompetent patients hospitalized in intensive care. Clinical Microbiology and Infection, 18, E221–E231.
[23] Boyer, K. M., Holfels, E., Roizen, N., et al. (2005). Risk factors for Toxoplasma gondii infection in mothers of infants with congenital toxoplasmosis. American Journal of Obstetrics and Gynecology, 193, xx–xx.
[24] Weiss, L. M., & Kim, K. (2011). Toxoplasma gondii: The model apicomplexan. Academic Press.
[25] Centers for Disease Control and Prevention. (2013). Parasites – Toxoplasmosis: Prevention and control. CDC.
[26] Centers for Disease Control and Prevention. (2019). Toxoplasmosis – Treatment. CDC.
[27] Brown, Z. A., Wald, A., Morrow, R. A., Selke, S., Zeh, J., & Corey, L. (2000). Effect of maternal herpes simplex virus infection on pregnancy outcome. New England Journal of Medicine, 342(16), 1165–1170.
[28] Gupta, R., Warren, T., & Wald, A. (2021). Genital herpes. The Lancet, 393(10187), 1710–1720.
[29] Rahman, M., Gupta, R., Singh, R., et al. (2020). Vertical transmission of malaria parasites and associated neonatal outcomes. Malaria Journal, 19, xx–xx.
[30] Krawitz, C., Fernandez, M., Ahmed, Y., et al. (2018). Diagnostic challenges of malaria in pregnancy: A systematic review. BMC Infectious Diseases, 18, xx–xx.
[31] McLean, A. R. D., Stanisic, D. I., McGready, R., et al. (2022). Malaria in pregnancy and adverse birth outcomes. Clinical Microbiology Reviews, 35(1), e00049–21.
[32] Easterling, T. R., Schminkey, D. L., Brown, H., et al. (2020). Clinical management of brucellosis in pregnant women: A global review. BMJ Open, 10, e034835.
[33] Roushan, M. R. H., Ahmadi, S. A., Ghasemi, A., et al. (2019). Brucellosis in pregnancy: Clinical features, diagnosis, and management. Journal of Infection in Developing Countries, 13(5), 399–405.
[34] Sayadi, M., Amiri, F. B., Safari, M., et al. (2021). TORCH infections and pregnancy complications: An updated review. Infectious Disorders – Drug Targets, 21(4), e170123.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Stallion Journal for Multidisciplinary Associated Research Studies
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
10.55544/sjmars
editor@sjmars.com | 
+91-8874396939
